ReviewPharmacotherapy2012
Antiangiogenic therapy for cancer: an update.
Review in Pharmacotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 216 citations in OpenAlex.
- Exploitation of enhanced prime editing for blocking aberrant angiogenesis.Journal of advanced research · 2025Article
- Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies.Biomarker research · 2025Review
- From Blood to Therapy: The Revolutionary Application of Platelets in Cancer-Targeted Drug Delivery.Journal of functional biomaterials · 2025Review
- Nanobody-functionalized liposomal doxorubicin: A novel strategy for angiogenesis suppression via VEGFR2 targeting.BioImpacts : BI · 2025Article
- New Carbothioamide and Carboxamide Derivatives of 3-Phenoxybenzoic Acid as Potent VEGFR-2 Inhibitors: Synthesis, Molecular Docking, and Cytotoxicity Assessment.Current cancer drug targets · 2025Article
- Review
- Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024Review
- Article
- Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies.Stem cells international · 2024Review
- Gastric cancer fibroblasts affect the effect of immunotherapy and patient prognosis by inducing micro-vascular production.Frontiers in immunology · 2024Article
- An Overview of the Use of Anti-Angiogenic Agents in the Treatment of Thymic Epithelial Tumors.International journal of molecular sciences · 2023Review
- Epigenetic regulation in lung cancer.MedComm · 2023Review
- KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomas.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Angiogenic signaling pathways and anti-angiogenic therapy for cancer.Signal transduction and targeted therapy · 2023Review
- An intuitionistic approach for the predictability of anti-angiogenic inhibitors in cancer diagnosis.Scientific reports · 2023Article
- Recent advances in 2D material-based phototherapy.Frontiers in bioengineering and biotechnology · 2023Review
- A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors.International journal of general medicine · 2023Article
- Intravital imaging and cavitation monitoring of antivascular ultrasound in tumor microvasculature.Theranostics · 2023Article
- Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial.Thrombosis and haemostasis · 2022Article
- Design Principles of Hybrid Nanomaterials for Radiotherapy Enhanced by Photodynamic Therapy.International journal of molecular sciences · 2022Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
The idea of antiangiogenic therapy was the brainchild of Dr. Judah Folkman in the early 1970s. He proposed that by cutting off the blood supply, cancer cells would be deprived of nutrients and, hence, treated. His efforts paid off when bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, was approved as antiangiogenic therapy in 2004 for the treatment of colon cancer. Since then, an array of antiangiogenic inhibitors, either as monotherapy or in combination with other cytotoxic and chemotherapy drugs, have been developed, used in clinical trials, and approved for the treatment of cancer. Despite this important breakthrough, antiangiogenic therapy for cancer met with a number of hurdles on its way to becoming an option for cancer therapy. In this article, we summarize the most current information on the mechanisms of tumor angiogenesis, proangiogenic and antiangiogenic factors, potential targets and their mechanisms of action, and experimental evidences, as well as the most recent clinical trial data on antiangiogenic agents for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.